Related Experiment Videos
Hydroxyurea in thalassemia intermedia--a promising therapy
Ashish Dixit1, T C Chatterjee, Pravas Mishra
1Department of Haematology, All India Institute of Medical Sciences, New Delhi, India.
Annals of Hematology
|April 20, 2005
Summary
Hydroxyurea (HU) therapy effectively treats beta-thalassemia intermedia, with most patients showing improved hemoglobin levels and reduced transfusion needs. A short HU trial can predict long-term response in these patients.
Area of Science:
- Hematology
- Pharmacology
Background:
- Hydroxyurea (HU) is known to induce fetal hemoglobin (HbF).
- HU may alleviate symptoms in beta-thalassemia intermedia patients.
Purpose of the Study:
- To assess the response of beta-thalassemia intermedia patients to hydroxyurea (HU) therapy.
- To identify predictors of response and evaluate the predictability of a short HU trial.
Main Methods:
- Thirty-seven beta-thalassemia intermedia patients were enrolled.
- Response was defined by transfusion independence, hemoglobin increase, or transfusion frequency reduction.
- Correlation with genetic factors and predictors of response were analyzed.
Main Results:
- 70.2% of patients responded to HU therapy, with 45.9% being major responders.
- Increased HbF levels were observed; older age and low baseline HbF predicted poor response.
- Response was typically evident within one month, suggesting a short trial is predictive.
Conclusions:
- Hydroxyurea therapy is effective in managing beta-thalassemia intermedia.
- A short-term HU trial can predict sustained therapeutic response.
- Predictors of poor response include older age and low baseline HbF levels.